A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State

Figures & data

Table 1. Time schedule of psychedelic questionnaire assessment and blood samples.

Data collection	T0	T1	T2	T3	T4–1	T4	T4 + 1	T5	T5 + 1
Time post-treatment	0	60 min	4 h	6 h	8 h	9 h	10 h	11 h	12 h
B-VAS	X	X	X					X
CADSS		X	X			X
5D-ASC						X
HRS								X
PCT				X
4-FA serum concentrations	X	X	X	X	X		X		X

Figure 1. Mean (±SE) of ratings on the two scales of the B-VAS (units on the left Y-axis)—i.e., (A) external perception and (B) internal perception—and the ratings on the three subscales of the CADSS (on the left Y-axis)—amnesia (C), depersonalization (D), derealization (E)—and the total dissociative score (F) in the placebo (•) and 4-FA condition (□) at 1 h post-treatment (T1), 4 h post-treatment (T2), and 9 h post-treatment (T4) for the B-VAS and 11 min post-treatment (T5) for the CADSS, and corresponding 4-FA serum concentrations (on the right Y-axis) in the 4-FA condition (•).

Table 2. Main and interaction effects of treatment and measurement on the subscales and total scale of the CADSS and mean (±SE) ratings on the six scales of the HRS, 11 hours post-treatment, and paired samples t-test values and corresponding p-values.

	Treatment (T)			Measurement (M)			T*M
CADSS Scales	F1,11	p	ƞp^2	F2,22	p	ƞp^2	F	p	ƞp^2
Amnesia	2.62	0.14	0.21	1.39	0.27	0.12	1.45	0.26	0.13
Depersonalization	9.96	0.01	0.50	5.16	0.02	0.34	6.18	0.008	0.38
Derealization	9.93	0.01	0.50	9.46	0.001	0.49	8.62	0.002	0.46
Total CADSS	8.86	0.01	0.47	7.76	0.003	0.44	7.91	0.003	0.44
	Treatment (Mean ±SE)		Paired Samples t-tests
HRS Scales	Placebo	4-FA	t11	p
Affect	0.30 (0.05)	1.12 (0.16)	−4.61	0.001
Perception	0.00 (0.00)	0.22 (0.05)	−4.50	0.001
Cognition	0.05 (0.04)	0.78 (0.17)	−4.34	0.001
Volition	2.03 (0.88)	1.33 (0.35)	2.75	0.02
Intensity	1.39 (0.05)	2.89 (0.22)	−6.62	<0.001
Somaesthesia	0.02 (0.02)	1.23 (0.22)	−5.61	<0.001

Figure 2. Main (±SE) ratings on the five dimensions of the 5D-ASC (panel A) and 11 lower-order 5D-ASC scales, OB (Panel B), AED (Panel C), and VR (Panel D) in the placebo (•) and 4-FA condition (□), * indicate statistically significant differences between treatment condition at alpha = –0.05.